EU regulatory nods for next-gen obesity and pancreatic cancer drugs

The European Medicines Agency’s Committee for Medicinal Products for Human Use backed multiple late-stage assets, including Eli Lilly’s oral GLP-1 therapy orforglipron. In the same regulatory window, EMA’s CHMP also endorsed RevMed’s first-in-class pancreatic cancer therapy, following rapid FDA approvals for related assets.